PURPOSE: In a previously reported randomized Southeastern Cancer Study Group (SECSG) trial, three cycles of chemotherapy were found to be equivalent to four cycles in @entity1 with favorable-prognosis germ-cell @entity5 . We have conducted a follow-up analysis of @entity1 treated at Indiana University (Indianapolis, IN) to compare long-term survival between the two groups and to examine factors associated with survival. @entity1 AND METHODS: Sixty-nine @entity1 with minimal-stage and 49 @entity1 with moderate-stage disseminated germ-cell @entity5 were randomized to either three or four courses of @entity1732 , @entity2879 , and @entity900 ( @entity12962 ) administered every 3 weeks. Median follow-up time is 10.1 years (range, 7 months to 12.6 years). Ninety-two percent of @entity1 have an actual follow-up time of > 5 years, and 97.5% of @entity1 have an actual follow-up time of > 3 years. RESULTS: Survival analysis shows no significant difference between the two treatment groups in terms of overall (P = .80) or disease-free (P = .93) survival. Several clinical variables were examined by univariate analysis; only serum @entity7103 ( @entity7103 ) had an impact on survival. There were two disease-related @entity204 in 104 @entity1 with @entity7103 < or = 1,000 mIU/mL and five disease-related @entity204 in 14 @entity1 with @entity7103 greater than 1,000 mIU/mL (P < .001). Ninety-eight percent (95% CI, 95.2 to 100) of @entity1 with favorable prognosis germ-cell @entity5 with an initial @entity7103 of < or = 1,000 mIU/mL are alive without evidence of disease at 5+ years. CONCLUSION: With long-term follow-up, there is no statistically significant difference in survival between three or four cycles of BEP chemotherapy in @entity1 with favorable prognosis germ-cell @entity189 . Serum @entity7103 elevation of greater than 1,000 mIU/mL is a significant predictor of poor outcome in @entity1 with otherwise good-risk disease.

Long-term follow-up of a phase III study of three versus four cycles of @entity1732 , XXXX , and @entity900 in favorable-prognosis germ-cell @entity5 : the Indian University experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity12962 :: ('CHEBI:34567', 'Chemical') :: ['BEP'] @entity7103 :: ('MESH:C535764', 'Disease') :: ['human chorionic gonadotropin', 'HCG'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity2879 :: (MESH:D005047,Chemical) :: ['etoposide']
